Expert Interview
Discussing the potential of EO-3021, a Claudin 18.2 ADC), and the Phase I trial in gastric (GC), gastroesophageal junction (GEJ), and pancreatic cancers.
Ticker(s): ELEV, ALPMYInstitution: Duke University
- Gastrointestinal Oncologist and Professor of Medicine in the Department of Surgery at Duke University
- Manages 30+ patients with pancreatic cancer
- Research interest in immune therapies for treating GI cancers
How do you currently treat gastric cancer?
Added By: sara_adminHow does EO-3021 compare to Astellas Claudin 18.2 candidate Zolbetuximab?
Added By: sara_adminWhat are your impressions of the data shown from the anti Claudin 18.2 therapies?
Added By: sara_adminWhat are the current treatment options for advanced gastric (GC), gastroesophageal junction (GEJ), and pancreatic cancers, and how are molecular markers like Claudin 18.2, PD-L1, HER2, and MSI used to guide therapy selection?
Added By: catalin_adminHow does the expression of Claudin 18.2 correlate with other biomarkers, and how is treatment determined when patients express multiple markers such as PD-L1 and Claudin 18.2?
Added By: catalin_adminWhat are your thoughts on the efficacy and safety of EO-3021 compared to other Claudin 18.2-targeting therapies, including zolbetuximab and ADCs like CMG901?
Added By: catalin_adminHow does the site-specific conjugation and lower MMAE toxicity of EO-3021 influence its tolerability and potential advantages in treating high Claudin 18.2-expressing patients?
Added By: catalin_adminWith zolbetuximab approved for earlier-line treatment, how will EO-3021 position itself in later lines of therapy, and what are the challenges in demonstrating efficacy in a heavily pre-treated population?
Added By: catalin_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
